How horizon scanning can help predict the future for EU’s Alzheimer’s disease market
Aduhelm’s US launch has prompted a new look into what is in store for the Alzheimer’s disease market over the coming years.
By
Eoin Ryan
Latest articles
All Articles
Irish green credentials fail on pharmaceutical waste exports
Foreign investment in Ireland’s pharmaceutical sector has gone from strength to strength in 2019. With major new multi-billion-dollar investment…
By
Accuracy check: Norwegian health expenditure data
The recent publication of Norway’s Statistik Sentralbyrå (SSB) annual healthcare and pharmaceutical expenditure statistics confirms the accuracy of IHS…
By
Italian pharma tendering set for new oversight in two-year outlook
Italy’s public procurement agency, CONSIP, has this month updated the list of pharmaceutical products under a 2017-21 tender with…
By
Norwegian pharma industry calls for tendering and IRP reforms
The pharmaceutical sector in Norway has responded to recent criticism levelled at the industry by healthcare authorities related to…
By
UK post-Brexit participation in unified patent court poses plenty of questions
The UK’s future eligibility to participate in the Unified Patent Court (UPC) and unitary patent system rests on a…
By
On the road to HTA harmonization in Europe
Last month’s proposals by the European Commission for the creation of a single, mandatory system for clinical health technology…
By
Amsterdam triumphs: Is the Netherlands a Trojan horse for pricing and drug approval reform in Europe?
Italy’s failure to win the EMA relocation vote has been likened to losing on penalties in the World Cup.…
By
Nordics inch toward cooperation on drug purchasing, but don’t expect early developments
In late March the Danish Institute for Local and Regional Government Research (KORA) published research mapping similarities and differences…
By